Scientific Workshops
The following information is preliminary and subject to change. All times are listed in Central time.
The Scientific Workshops are interactive discussions of the latest scientific developments in a particular field of hematology. These workshops will take place on Friday, December 9 and each will be 3-hours long. All registered ASH annual meeting attendees are welcome to attend these workshops; there is no fee to attend.
December 10, 2021, 2:00 p.m. - 5:00 p.m. Eastern time
This workshop will focus on risk prediction and assessment in non-malignant and malignant hematologic diseases, examining the translation of results of observational and association studies to clinically relevant risk prediction and assessment. Disparities-based risk assessment (including the incorporation of race- and gender into risk assessment and prediction models) will be highlighted across the sessions.
Topics to be covered in this workshop include current knowledge of assessment of risk of primary and secondary malignancies after exposure to radiation, the predictive role of the microbiome in response to therapy for diffuse large B-cell lymphoma, race-based prediction of malignant transformation from monoclonal gammopathy of undetermined significance to multiple myeloma, assessment of venous thromboembolism lipoprotein and stroke risk, risk of thrombosis in myeloma patients related to immunomodulatory drugs, and the role of CHIP in predicting both cardiovascular disease and myeloid malignancies, and development of a cohort of hematologic neoplasms patients to study response to COVID-19 vaccination.
Workshop Schedule
Opening Remarks
2:00 p.m. - 2:02 p.m.
Eastern time
Georgia World Congress Center, B401-B402, Level 4
Moderators:
Wendy Cozen
, DO,MPH
University of California, Irvine
Irvine,
CA
James R. Cerhan
, MD, PhD
Mayo Clinic
Rochester,
MN
Myeloid Malignancy Risk Prediction and Assessment
2:03 p.m. - 2:49 p.m.
Eastern time
Georgia World Congress Center, B401-B402, Level 4
Moderator:
James M. Foran
, MD
Mayo Clinic Florida
Jacksonville,
FL
Speakers:
James M. Foran
, MD
Mayo Clinic Florida
Jacksonville,
FL
Moderator Introduction
Kelly L Bolton
, MD
Washington University In St Louis
St Louis,
MO
What Can Clonal Hematopoiesis Teach Us about Secondary Hematologic Malignancies?
Kelly L Bolton
, MD
Washington University In St Louis
St Louis,
MO
Q&A
Angela Fleischman
, MD, PhD
University of California, Irvine
Irvine,
CA
A Family Registry of MPN and a Potential Predictive Phenotype.
Angela Fleischman
, MD, PhD
University of California, Irvine
Irvine,
CA
Q&A
Mohamed L. Sorror
, MD, MSc
Fred Hutchinson Cancer Research Center
Seattle,
WA
Risk Assessment, Prediction and Decision Making for Patients with Acute Myeloid Leukemia
Mohamed L. Sorror
, MD, MSc
Fred Hutchinson Cancer Research Center
Seattle,
WA
Q&A
Lymphoid Malignancy Risk Prediction and Assessment
2:50 p.m. - 3:36 p.m.
Eastern time
Georgia World Congress Center, B401-B402, Level 4
Moderators:
Wendy Cozen
, DO,MPH
USC Norris Comprehensive Cancer Center
Manhattan Beach,
CA
James R. Cerhan
, MD, PhD
Mayo Clinic
Rochester,
MN
Speakers:
James R. Cerhan
, MD, PhD
Mayo Clinic
Rochester,
MN
Moderator Introduction
Catherine S. Diefenbach
, MD
Perlmutter Cancer Center at NYU Langone Health
New York,
NY
The Role of the Microbiome in Systemic Immunity and Lymphoma Outcome
Catherine S. Diefenbach
, MD
Perlmutter Cancer Center at NYU Langone Health
New York,
NY
Q&A
Susan L. Slager
, PhD
Mayo Clinic
Rochester,
MN
Risk Assessment in CLL Families: Monoclonal B-Cell Lymphocytosis Incidence and Progression to CLL
Susan L. Slager
, PhD
Mayo Clinic
Rochester,
MN
Q&A
Ritu Gupta
, MD
Laboratory Oncology, Dr. BRAIRCH
New Delhi,
India
Clinical Impact of Ethnic Differences on Multiple Myeloma Risk Prediction in the Era of Genomics and Novel Agents
Ritu Gupta
, MD
Laboratory Oncology, Dr. BRAIRCH
New Delhi,
India
Q&A
Benign Hematology Risk Prediction and Assessment
3:41 p.m. - 4:57 p.m.
Eastern time
Georgia World Congress Center, B401-B402, Level 4
Moderator:
Neil A. Zakai
, MD,MSc
Fletcher Allen Health Care, University of Vermont
Burlington,
VT
Speakers:
Neil A. Zakai
, MD,MSc
Fletcher Allen Health Care, University of Vermont
Burlington,
VT
Introduction to Benign Hematology Risk Prediction and Assessment
Rushad Patell
, MBBS
Beth Israel Deaconess Medical Center
Boston,
MA
Prediction of VTE Risk in People with Cancer.
Rushad Patell
, MBBS
Beth Israel Deaconess Medical Center
Boston,
MA
Q&A
Monia Marchetti
Hematology Unit, Az Osp SS Antonio e Biagio e Cesare Arrigo
Alessandria,
Italy
VTE Risk Prediction Scores in Clinical Practice Guidelines of Blood Cancers: Advantages and Pitfalls
Monia Marchetti
Hematology Unit, Az Osp SS Antonio e Biagio e Cesare Arrigo
Alessandria,
Italy
Q&A
Pamela L Lutsey
, PhD, MPH
University of Minnesota
Minneapolis,
MN
Venous Thromboembolism Epidemiology: Considerations of Risk in Diverse Populations
Pamela L Lutsey
, PhD, MPH
University of Minnesota
Minneapolis,
MN
Q&A
Babak Navi
, MD,MS
Weill Cornell Medicine
New York,
NY
Thrombophilia and Ischemic Stroke Risk: What Does Epidemiology Teach Us
Babak Navi
, MD,MS
Weill Cornell Medicine
New York,
NY
Q&A
Jordan K Schaefer
, MD
University of Michigan
Ann Arbor,
MI
Pharmacoepidemiology: Antithrombotics and COVID-19 Outcomes
Jordan K Schaefer
, MD
University of Michigan
Ann Arbor,
MI
Q&A
December 10, 2021, 2:00 p.m. - 5:00 p.m. Eastern time
The importance of identifying individuals with germline mutations that confer susceptibility to hematopoietic malignancies (HM) and bone marrow failure (BMF) is increasingly recognized. Presentations at this workshop will feature updates on scientific progress in disorders of inherited HMs and BMF, highlighting preclinical research aimed at understanding the genes and mechanisms that confer elevated risk, and work that ultimately improves diagnosis and patient management.
This year, sessions will focus on DNA repair pathways; variant interpretation and modeling; new scientific and syndrome discoveries; and ribosomopathies.
This workshop will engage investigators from across the world to foster diverse representation of speakers and topics, a collaborative spirit, and new international collaborations.
Workshop Schedule
Opening Remarks
2:00 p.m. - 2:01 p.m.
Eastern time
Georgia World Congress Center, B211-B212, Level 2
Moderator:
Marcin Wlodarski
, MD, PhD
St. Jude Children's Research Hospital
Memphis,
TN
DNA Repair and Malignancy
2:02 p.m. - 2:46 p.m.
Eastern time
Georgia World Congress Center, B211-B212, Level 2
Moderators:
Wojciech Mlynarski
, Prof, MD, PhD
Medical University of Lodz
Lodz,
Poland
Richa Sharma
, MD
St Jude Children's Research Hospital
Memphis,
TN
Speakers:
Edward Chew
, PhD
The Walter & Eliza Hall Institute of Medical Research
Parkville,
AUS
MBD4 Associated Neoplasm Syndrome: A Tale of Blood and Guts
Edward Chew
, PhD
The Walter & Eliza Hall Institute of Medical Research
Parkville,
AUS
Live Q&A
Brittany L Griffin
, MS, PhD
Cleveland Clinic Foundation
Cleveland,
OH
Germline Biallelic Loss in MBD4 Leading to Early Onset AML with Hyper-Mutator Genomic Signatures
Brittany L Griffin
, MS, PhD
Cleveland Clinic Foundation
Cleveland,
OH
Live Q&A
Anase Asom
, BS
University of Chicago
Chicago,
IL
The Role of Germline CHEK2 Variants in Hematologic Malignancies
Anase Asom
, BS
University of Chicago
Chicago,
IL
Q&A
Hannah Armes
, PhD
Queen Mary University of London
London,
United Kingdom
Germline ERCC6L2 Mutations Lead to Impaired Erythropoiesis and Reshaping of the Bone Marrow Niche
Hannah Armes
, PhD
Queen Mary University of London
London,
United Kingdom
Live Q&A
Agata Smogorzewska
, MD
The Rockefeller University
New York,
NY
Fanconi Anemia Pathway Deficiency Drives Copy Number Variation in Squamous Cell Carcinomas
Agata Smogorzewska
, MD
The Rockefeller University
New York,
NY
Live Q&A
Variant Interpretation and Disease Modeling - Quick Fire Talks
2:47 p.m. - 3:16 p.m.
Eastern time
Georgia World Congress Center, B211-B212, Level 2
Moderators:
Julia T Warren
, MD, PhD
Washington University School of Medicine
Saint Louis,
MO
Christian P. Kratz
, MD
Hannover Medical School
Hannover,
Germany
Speakers:
Sara Lewis
St. Jude Children's Research Hospital
Memphis,
TN
Registry for Individuals with Germline SAMD9 and SAMD9L Mutations
Taylor Walker
University of Chicago
Chicago,
IL
Use of a Modified-Delphi Approach to Define the Pleiotropic GATA2-Deficient Phenotype for the Development of Acmg-AMP GATA2 Variant Curation Rules
Parvathy Venugopal
, PhD
Centre for Cancer Biology, SA Pathology and University of South Australia
Adelaide,
Australia
Modelling a Germline Mutation to Understand Phenotypes Associated with GATA2 Deficiency Syndrome
Oded Gilad
, MD
Tel Aviv University
Tel Aviv,
Israel
Syndromes Predisposing to Leukemia Are a Major Cause of Inherited Cytopenias in Children
Eunice Sindhuvi Edison
, PhD
Christian Medical College
Vellore,
Tamilnadu, India
Germline Variants Contribute Significantly to the Pathogenesis of Aplastic Anemia in India
Saumya E Samaraweera
, PhD
University of South Australia
Adelaide,
Australia
Childhood Acute Myeloid Leukemia Shows a High Level of Germline Predisposition
Hideki Makishima
, MD, PhD
Kyoto University
Kyoto,
JPN
Predisposition and Clinical Impact of DDX41 Germline Mutations in Myeloid Neoplasms
Moderators:
Julia T Warren
, MD, PhD
Washington University School of Medicine
Saint Louis,
MO
Christian P. Kratz
, MD
Hannover Medical School
Hannover,
Germany
Speakers:
Christopher R. Reilly
, MD
Dana-Farber Cancer Institute
Boston,
MA
Making Sense out of Missense: The Clinical and Functional Effects of Germline TERT Variants in MDS
Christopher R. Reilly
, MD
Dana-Farber Cancer Institute
Boston,
MA
Live Q&A
Timothy M Chlon
, PhD
Cincinnati Children's Hospital
Cincinnati,
OH
Modelling DDX41-Mutant MDS
Timothy M Chlon
, PhD
Cincinnati Children's Hospital
Cincinnati,
OH
Live Q&A
Anupriya Agarwal
, PhD
Oregon Health & Science University
Portland,
OR
Context-Dependent Mechanisms of Defective Hematopoiesis in RUNX1-Familial Platelet Disorder
Anupriya Agarwal
, PhD
Oregon Health & Science University
Portland,
OR
Live Q&A
Ribosomopathies
3:46 p.m. - 4:14 p.m.
Eastern time
Georgia World Congress Center, B211-B212, Level 2
Moderators:
Kasiani C. Myers
, MD
Cincinnati Children's Hospital
Cincinnati,
OH
Lionel Blanc
, PhD
The Feinstein Institutes for Medical Research
Manhasset,
NY
Speakers:
Deena Iskander
, MD
Imperial College London
London,
United Kingdom
Single-Cell Profiling of Human Bone Marrow Progenitors Reveals Mechanisms of Failing Erythropoiesis in Diamond-Blackfan Anemia
Deena Iskander
, MD
Imperial College London
London,
United Kingdom
Live Q&A
Yuefeng Tang
, PhD
Northwell Health
Manhasset,
NY
Conditional Deletion of Exon 2 in Rps19 Leads to Bone Marrow Failure and Absence of Stress Erythropoiesis in a Mouse Model of Diamond Blackfan Anemia
Yuefeng Tang
, PhD
Northwell Health
Manhasset,
NY
Live Q&A
Senthil Velan Bhoopalan
, PhD,MBBS
St. Jude Children's Research Hospital
Memphis,
TN
TP53-Dependent Hematopoietic Stem Cell Defect in RPS19 Gene-Edited CD34+ Cells
Senthil Velan Bhoopalan
, PhD,MBBS
St. Jude Children's Research Hospital
Memphis,
TN
Live Q&A
New Discoveries
4:15 p.m. - 4:59 p.m.
Eastern time
Georgia World Congress Center, B211-B212, Level 2
Moderators:
Deepak Singhal
, MBBS, MD, FRCPA, FRACP
Royal Adelaide Hospital, University of Adelaide
Adelaide,
Australia
Ana Rio-Machin
, PhD
Queen Mary University of London
London,
United Kingdom
Speakers:
Patrycja M Dubielecka
, PhD
Warren Alpert Medical School of Brown University
Providence,
Whole Genome Sequencing Identifies a Recurrent Mutation in Complement Factor I in Primary Myelofibrosis
Patrycja M Dubielecka
, PhD
Warren Alpert Medical School of Brown University/Rhode Island Hospital
Providence,
RI
Live Q&A
Anne Davidson
, MBBS
The Feinstein Institutes for Medical Research, Northwell Health
Manhasset,
NY
Overexpression of Human TLR8 Causes Fatal Anemia in SLE-Prone Mice Byaltering the Bone Marrow Erythropoietic Niche
Anne Davidson
, MBBS
The Feinstein Institutes for Medical Research, Northwell Health
Manhasset,
NY
Live Q&A
Vijay G. Sankaran
, MD,PhD
Boston Children's Hospital
Boston,
MA
Insights from Rare Variant Association Studies of Myeloid Malignancies
Vijay G. Sankaran
, MD,PhD
Boston Children's Hospital
Boston,
MA
Live Q&A
Julia Skokowa
, MD, Ph.D.
University Hospital Tuebingen
Tuebingen,
Germany
Novel Experimental Model of Stepwise Leukemogenesis Provides Therapeutic Opportunities for Severe Congenital Neutropenia
Julia Skokowa
, MD, Ph.D.
University Hospital Tuebingen
Tuebingen,
Germany
Live Q&A
Agata Karolina Pastorczak
, MD, PhD
Medical University of Lodz
Lodz,
Poland
Molecular Specific Features of Diffuse Large B-Cell Lymphoma in Children with Nijmegen Breakage Syndrome
Agata Karolina Pastorczak
, MD, PhD
Medical University of Lodz
Lodz,
Poland
Live Q&A
December 10, 2021, 2:00 p.m. - 5:00 p.m. Eastern time
Older adults with hematologic disorders are a growing demographic yet remain understudied and are vulnerable to both disease and age-related morbidity and mortality. Improving the approach to care for older adults with hematologic disorders requires appreciation of the basic science of aging as well as differences in disease diagnosis, response, and tolerance to treatment.
This workshop aims to highlight key scientific advances in the aging and hematology field. In addition, the workshop aims to partner investigators within ASH with key participants in the broader geroscience community to advance hematology and aging research.
The workshop will utilize an interactive format and provide opportunities for early career investigators to share their research and demonstrate their leadership.
Workshop Schedule
Opening Remarks
2:00 p.m. - 2:03 p.m.
Eastern time
Georgia World Congress Center, B207-B208, Level 2
Speaker:
Andrew S. Artz
, MD,MS
City of Hope
Duarte,
CA
Introduction
Keynote Address
2:04 p.m. - 2:19 p.m.
Eastern time
Georgia World Congress Center, B207-B208, Level 2
Speaker:
Paige Green
, PhD, MPH,FABMR
National Cancer Institute
Bethesda,
MD
NCI Perspective and Funding Opportunities
Hematopoietic Stem Cell Accelerated Aging
2:20 p.m. - 2:54 p.m.
Eastern time
Georgia World Congress Center, B207-B208, Level 2
Moderator:
Andrew S. Artz
, MD,MS
City of Hope
Duarte,
CA
Speakers:
Andrew S. Artz
, MD,MS
City of Hope
Duarte,
CA
Moderator Introduction
Isabel Beerman
, PhD
National Institute on Aging, NIH
Baltimore,
MD
Epigenetic Analysis on Young and Aged Hematopoietic Stem Cells
Kristina Kirschner
, PhD
CRUK Beatson Institute
Bearsden,
United Kingdom
Longitudinal Dynamics of Clonal Hematopoiesis Identifies Gene-Specific Fitness Effects
Aging, Immunity, and Bone Marrow Microenvironment
2:59 p.m. - 3:44 p.m.
Eastern time
Georgia World Congress Center, B207-B208, Level 2
Moderator:
Ashley E. Rosko
, MD
The Ohio State University
Columbus,
OH
Speakers:
Ashley E. Rosko
, MD
The Ohio State University
Columbus,
OH
Moderator Introduction
Curtis J Henry
, PhD
Emory University School of Medicine
Atlanta,
GA
Delineating the Impact of Interleukin-37 on Anti-Cancer Immunity in Aged Backgrounds
Amina Abdul-Aziz
, PhD
University of Cincinnati
Cincinnati,
OH
Senescence and Aging in the AML Microenvironment
Michaela R Reagan
, PhD
Maine Medical Center Research Institute
South Portland,
ME
Bone Marrow Adipocytes in Aging and Multiple Myeloma
Personalizing Malignant Hematology Care Based on Aging Phenotypes
3:49 p.m. - 4:50 p.m.
Eastern time
Georgia World Congress Center, B207-B208, Level 2
Moderators:
Heidi D. Klepin
, MD,MS
Wake Forest School of Medicine
Winston Salem,
NC
Shakira J. Grant
, MBBS
The University of North Carolina at Chapel Hill
Chapel Hill,
NC
Speakers:
Shakira J. Grant
, MBBS
Pennsylvania Hospital
Chapel Hill,
NC
Moderator Introduction
Reinhard Stauder
, MD
Innsbruck Medical University
Innsbruck,
Austria
Integration of Patient-Reported and Patient-Oriented Factors in Health Care of Older Patients with Myelodysplastic Syndromes
Philip H. Imus
, MD
Columbia University
Baltimore,
MD
Aging, Myeloid Recovery, and Resilience after Allogeneic BMT
Alessandra Tucci
, MD
Department of Hematology, ASST Spedali Civili
Brescia,
Italy
Prognostication By Geriatric Assessment in Hodgkin Lymphoma
Lisa K. Hicks
, MD, MSc
Co-Chair of the ASH RC COVID-19 Registry Malignant Task Force
D.C.,
WA
Exploring the Impact of Advanced Age on COVID19 Outcomes and Treatment Patterns in the ASH RC COVID-19 Malignant Registry
December 10, 2021, 2:00 p.m. - 5:00 p.m. Eastern time
Pregnancy is a unique biologic state characterized by changes in coagulation system and immune tolerance. This workshop fills a gap in understanding physiologic changes in pregnancy and their interplay in development and course of hematologic diseases.
Autoimmunity can complicate pregnancy or be triggered by maternofetal antigenic disparity. Autoimmune hemolytic anemia is a rare and unique complication of pregnancy. Evolving evidence is pointing to a role of excessive complement activation in pathogenesis of pregnancy complications such as APLS, CM-HUS and HELLP syndrome. Endothelial damage in COVID-19 infection can trigger activation of coagulation and complement system in pregnancy leading to thrombosis and pregnancy loss. More recently SARS-CoV-2 vaccination has been associated with unique hematologic complications.
Advances in prenatal testing allow detection of predisposition to development of pregnancy associated diseases such as FNAIT; use of cell-free DNA allows early non-invasive identification of fetal genetic disorders such as hemophilia. Progress in gene editing methodologies hold the potential of early correction of the genetic defects in hemophilia and other disorders.
This workshop will serve as an introduction to the new scientific discoveries in this arena.
Workshop Schedule
Opening Remarks
2:00 p.m. - 2:04 p.m.
Eastern time
Georgia World Congress Center, B304-B305, Level 3
Moderators:
Shannon M. Bates
, MD,FRCPC,MSc
McMaster University
Hamilton,
ON, Canada
Irina Murakhovskaya
, MD
Montefiore Hospital, Albert Einstein College of Medicine
Bronx,
NY
Henny H. Billett
, MD, MSc
Montefiore Medical Center, Albert Einstein College of Medicine
Bronx,
NY
Immunohematology in Pregnancy
2:05 p.m. - 3:10 p.m.
Eastern time
Georgia World Congress Center, B304-B305, Level 3
Moderator:
Shruti Chaturvedi
, MBBS
Johns Hopkins University School of Medicine
Baltimore,
MD
Speakers:
Shruti Chaturvedi
, MBBS
Johns Hopkins University School of Medicine
Baltimore,
MD
Moderator Introduction
Bruno Fattizzo
, MD
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico e Università degli Studi
Milan,
Italy
Autoimmune Hemolytic Anemia in Pregnancy
Fadi Fakhouri
University of Lausanne
Lausanne,
Switzerland
AHUS and Pregnancy
Shruti Chaturvedi
, MBBS
Johns Hopkins University School of Medicine
Baltimore,
MD
Emerging Evidence on Preeclampsia and APLS
COVID, COVID Vaccines, and Pregnancy
3:11 p.m. - 4:00 p.m.
Eastern time
Georgia World Congress Center, B304-B305, Level 3
Moderator:
Menaka Pai
, BSc,MD,FRCPC,MSc
McMaster University
Hamilton,
Canada
Speakers:
Menaka Pai
, BSc,MD,FRCPC,MSc
McMaster University
Hamilton,
ON, Canada
Moderator Introduction
A. Kinga Malinowski
, MD
Mt. Sinai Hospital
Toronto,
ON, Canada
Hematologic Aspects of COVID in Pregnancy
Menaka Pai
, BSc,MD,FRCPC,MSc
McMaster University
Hamilton,
ON, Canada
Hematologic Complications of COVID Vaccination
Prenatal Testing and Potential Therapy
4:01 p.m. - 4:58 p.m.
Eastern time
Georgia World Congress Center, B304-B305, Level 3
Moderator:
Henny H. Billett
, MD, MSc
Montefiore Medical Center, Albert Einstein College of Medicine
Bronx,
NY
Speakers:
Henny H. Billett
, MD, MSc
Montefiore Medical Center, Albert Einstein College of Medicine
Bronx,
NY
Moderator Introduction
Craig D. Seaman
University of Pittsburgh
Pittsburgh,
PA
Next Generation Sequencing and Non-Invasive Prenatal Testing
Lani Lieberman
, MD
University of Toronto
Toronto,
ON, Canada
Fetal and Neonatal Alloimmune Thrombocytopenia
David Stitelman
, MD
Yale School of Medicine
New Haven,
CT
Prenatal Gene Therapy in Hematologic Disorders
December 10, 2021, 2:00 p.m. - 5:00 p.m. Eastern time
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer and cancer patients are the highest risk group for developing VTE. Despite considerable epidemiologic research, the mechanism of thrombosis in cancer is poorly understood.
This interactive workshop will discuss gaps in knowledge and ongoing investigations into how the coagulation system affects cancer progression and how therapy can modulate risk in myeloproliferative neoplasms and solid tumors.
This workshop will also provide a unique forum to discuss the mechanisms of thrombosis in hematologic malignancies, a topic that bridges malignant and non-malignant hematology within ASH.
Workshop Schedule
Opening Remarks
2:00 p.m. - 2:05 p.m.
Eastern time
Georgia World Congress Center, B308-B309, Level 3
Moderators:
Lisa Baumann Kreuziger
, MD
Versiti Blood Center of Wisconsin
Menomonee Falls,
WI
Jeffrey I. Zwicker
, MD
Beth Israel Deaconess Medical Center Harvard Medical School
Boston,
MA
Interplay Between the Hematologic System and Solid Tumor Progression
2:06 p.m. - 2:46 p.m.
Eastern time
Georgia World Congress Center, B308-B309, Level 3
Moderators:
Alisa S. Wolberg
, PhD
University of North Carolina At Chapel Hill
Chapel Hill,
NC
Christophe Dubois
Aix Marseille Universit%26#X00e9;
Marseille,
France
Speakers:
Alisa S. Wolberg
, PhD
University of North Carolina At Chapel Hill
Chapel Hill,
NC
Moderator Introduction
Westrick J Randal
, PhD
Oakland University
rochester hills,
MI
PAI-2 Deficiency and Accelerated Tumor Growth .
Westrick J Randal
, PhD
Oakland University
rochester hills,
MI
Q&A
Paul Jurasz
University of Alberta
Edmonton,
AB, Canada
Platelets and Pdl-1
Paul Jurasz
University of Alberta
Edmonton,
AB, Canada
Q&A
Claudine S Bonder
, PhD
Hanson Institute, Institute of Medical and Veterinary Science
Adelaide,
SA, Australia
Platelets and Vasculogenic Mimicry By Cancer Cells
Claudine S Bonder
, PhD
University of South Australia
Adelaide,
SA, Australia
Q&A
Biomarkers and Cancer Associated Thrombosis
2:47 p.m. - 3:27 p.m.
Eastern time
Georgia World Congress Center, B308-B309, Level 3
Moderators:
Mary Cushman
, MD
Larner College of Medicine at the University of Vermont
Colchester,
VT
Cihan Ay
Medical University of Vienna
Vienna,
Austria
Speakers:
Mary Cushman
, MD
Larner College of Medicine at the University of Vermont
Colchester,
VT
Moderator Introduction
Nadim Tawil
, PhD
McGill University
Montreal,
QC, Canada
Podoplanin and Procoagulant Extracellular Vesicles in Glioma
Nadim Tawil
, PhD
McGill University
Montreal,
QC, Canada
Q&A
Simon Mantha
, MD,MPH
Memorial Sloan Kettering Cancer Center
New York,
NY
Genomic Profiling and Thrombosis in Cancer
Simon Mantha
, MD,MPH
Memorial Sloan Kettering Cancer Center
New York,
NY
Q&A
Marc Carrier
, MD
University of Ottawa
Ottawa,
ON, Canada
Growth Differentiation Factor-15 and Bleeding in Cancer
Marc Carrier
, MD
University of Ottawa
Ottawa,
ON, Canada
Q&A
Hematologic Malignancy and Thrombosis
3:37 p.m. - 4:17 p.m.
Eastern time
Georgia World Congress Center, B308-B309, Level 3
Moderators:
Ayalew Tefferi
, MD
Mayo Clinic
Rochester,
MN
Casey L. O'Connell
, MD
University of Southern California
Los Angeles,
CA
Speakers:
Casey L. O'Connell
, MD
University of Southern California
Los Angeles,
CA
Moderator Introduction
Anish V. Sharda
, MBBS
Harvard Medical School
Brookline,
MA
Protein Disulfide Isomerase and Thrombosis in MPN
Anish V. Sharda
, MBBS
Harvard Medical School
Brookline,
MA
Q&A
Radhika Gangaraju
, MD
University Of Alabama
Birmingham,
AL
HIF-Regulated Genes and Thrombosis in MPN
Radhika Gangaraju
, MD
University Of Alabama
Birmingham,
AL
Q&A
Anandi Krishnan
, PhD
Stanford University School of Medicine
Palo Alto,
CA
Thromboinflammatory Signatures in MPN
Anandi Krishnan
, PhD
Stanford University School of Medicine
Palo Alto,
CA
Q&A
Late-Breaking Research Presentations
4:18 p.m. - 4:58 p.m.
Eastern time
Georgia World Congress Center, B308-B309, Level 3
Moderators:
Lisa Baumann Kreuziger
, MD
Versiti, Blood Research Institute
Milwaukee,
WI
Jeffrey I. Zwicker
, MD
Beth Israel Deaconess Medical Center Harvard Medical School
Boston,
MA
Speakers:
Jeffrey I. Zwicker
, MD
Beth Israel Deaconess Medical Center Harvard Medical School
Boston,
MA
Moderator Introduction
Yohei Hisada
, Ph.D.
University of North Carolina at Chapel Hill
Chapel Hill,
NC
Mechanisms of Hypercoagulability in Different Types of Acute Leukemia: Roles of Tissue Factor-Positive and Phosphatidylserine-Positive Extracellular Vesicles
Yohei Hisada
, Ph.D.
University of North Carolina At Chapel Hill
Chapel Hill,
NC
Q&A
Alok A Khorana
, MD
CLEVELAND CLINIC - US
Cleveland,
OH
Biomarker Signatures in Cancer Patients with and without Venous Thromboembolism Events: A Substudy of Cassini
Alok A Khorana
, MD
CLEVELAND CLINIC - US
Cleveland,
OH
Q&A
Ana Luisa Palacios-Acedo
, MD,MSc
Aix-Marseille Université
Marseille,
France
Tipping the Hemostatic Balance in Cancer: A Multi-Player Game
Ana Luisa Palacios-Acedo
, MD,MSc
Aix-Marseille Université
Marseille,
France
Q&A
December 10, 2021, 2:00 p.m. - 5:00 p.m. Eastern time
The workshop will cover the basic science of myeloid development and there will be no presentations on clinical/treatment strategies. The research that will be presented will utilize the tools of molecular biology, biochemistry, and animal models to address these topics. The research discussed will not include purely clinical, epidemiologic, or population-based approaches.
Workshop Schedule
Moderators:
Ross L. Levine
, MD
Memorial Sloan Kettering Cancer Center
New York,
NY
Patricia Ernst
, PhD
University of Colorado Denver, Anschutz Medical Campus
Aurora,
CO
Moderator:
Eric Pietras
, PhD
University of Colorado
Aurora,
CO
Speakers:
Eric Pietras
, PhD
University of Colorado
Aurora,
CO
Moderator Introduction
Yoon-A Kang
, PhD
Washington University School of Medicine
St. Louis,
MO
Secretory MPP3 Reinforce Myeloid Differentiation Trajectory and Amplify Myeloid Cell Production
Yoon-A Kang
, PhD
Washington University School of Medicine
New York,
NY
Q&A
Robert Signer
, PhD
UC San Diego
La Jolla,
CA
Crosstalk between Autophagy and the Proteasome Coordinates Hematopoietic Stem Cell Quiescence, Proteostasis and Cell Fate Determination
Robert Signer
, PhD
Moores Cancer Center
La Jolla,
CA
Q&A
Kevin Rouault-Pierre
, PhD
Barts Cancer Institute, Queen Mary University of London
London,
United Kingdom
SF3B1 Mutation in Myelodysplasia Induces Depletion of Key Substrates of the Heme Synthesis
Kevin Rouault-Pierre
, PhD
Barts Cancer Institute, Queen Mary University of London
London,
United Kingdom
Q&A
Katie L Kathrein
, PhD
University of South Carolina
Columbia,
SC
Ing4-Deficiency Enhances Hematopoietic Stem Cell Quiescence and Confers Resistance to Inflammatory Stress
Katie L Kathrein
, PhD
University of South Carolina
Columbia,
SC
Q&A
Transcription Factors and Epigenetics
2:48 p.m. - 3:29 p.m.
Eastern time
Georgia World Congress Center, B312-B314
Moderator:
Ulrich G. Steidl
, MD,PhD
Albert Einstein College of Medicine
Bronx,
NY
Speakers:
Ulrich G. Steidl
, MD,PhD
Albert Einstein College of Medicine
Bronx,
NY
Moderator Introduction
Nina Cabezas-Wallscheid
, PhD
Max-Planck-Institute of Immunobiology and Epigenetics
Freiburg,
Germany
Multilayer-Omics Analysis Reveals a Non-Classical Retinoic Acid Receptor Signaling Axis That Regulates Hematopoietic Stem Cell Identity
Nina Cabezas-Wallscheid
, PhD
Max-Planck-Institute of Immunobiology and Epigenetics
Freiburg,
Germany
Q&A
Vikram R Paralkar
, MD
University of Pennsylvania
Philadelphia,
PA
An Atlas of Hematopoietic Transcription Factor Binding to rDNA Reveals a Role for CEBPA in rRNA Regulation
Vikram R Paralkar
, MD
University of Pennsylvania
Philadelphia,
PA
Q&A
Kristy Stengel
, PhD
Albert Einstein College of Medicine
Bronx,
NY
Targeted Transcription Factor Degradation Defines Gene Networks and Mechanism of Action
Kristy Stengel
, PhD
Albert Einstein College of Medicine
Bronx,
NY
Q&A
Stanley C Lee
, PhD
Fred Hutchinson Cancer Research Center
Seattle,
WA
Spliceosome Mutant Leukemias Are Preferentially Sensitive to PARP1 Inhibition
Stanley C Lee
, PhD
Fred Hutchinson Cancer Research Center
Seattle,
WA
Q&A
Hematologic Malignancies
3:34 p.m. - 4:15 p.m.
Eastern time
Georgia World Congress Center, B312-B314
Moderator:
Benjamin L. Ebert
, MD
Department of Medical Oncology, Dana-Farber Cancer Institute
Boston,
MA
Speakers:
Benjamin L. Ebert
, MD
Department of Medical Oncology, Dana-Farber Cancer Institute
Boston,
MA
Moderator Introduction
Shruti Bhatt
, PhD
National University of Singapore
Singapore,
Singapore
Unraveling Basis of Resistance to Acute Myeloid Leukemia Therapy
Shruti Bhatt
, PhD
National University of Singapore
Singapore,
Singapore
Q&A
Liling Wan
, PhD
University of Pennsylvania
Philadelphia,
PA
Targeting Chromatin Reader-Mediated Transcriptional Programs in Acute Myeloid Leukemia.
Liling Wan
, PhD
University of Pennsylvania
Philadelphia,
PA
Q&A
Julie-Aurore Losman
, MD, PhD
Dana Farber Cancer Institute
Boston,
MA
R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Tumorigenesis in IDH-Mutant Cancers
Julie-Aurore Losman
, MD, PhD
Dana Farber Cancer Institute
Boston,
MA
Q&A
Paolo Gallipoli
, MD
University of Cambridge
London,
United Kingdom
Leveraging Metabolic Dependencies to Overcome Therapy Resistance in AML
Paolo Gallipoli
, MD
University of Cambridge
London,
United Kingdom
Q&A
Signaling and Development
4:16 p.m. - 4:57 p.m.
Eastern time
Georgia World Congress Center, B312-B314
Moderator:
Claudia Lengerke
, MD
University Hospital Tübingen
Tübingen,
Germany
Speakers:
Claudia Lengerke
, MD
University Hospital Tübingen
Tübingen,
Germany
Moderator Introduction
Courtney L Jones
, PhD
University of Toronto
Toronto,
ON, Canada
SIRT3 Inhibition Targets Leukemia Stem Cells By Disrupting Lipid Metabolism
Courtney L Jones
, PhD
University of Toronto
Toronto,
ON, Canada
Q&A
Raajit Rampal
, MD, PhD
Memorial Sloan Kettering Cancer Institute
New York,
NY
BMP/SMAD Pathway As a Mediator of Leukemic Transformation of Tp53 Mutant MPNs
Raajit Rampal
, MD, PhD
Memorial Sloan Kettering Cancer Institute
New York,
NY
Q&a
Shannon McKinney-Freeman
, PhD
St. Jude Children's Research Hospital
Memphis,
TN
Murine Fetal Bone Marrow Does Not Support Functional Hematopoietic Stem and Progenitor Cells until Birth
Shannon McKinney-Freeman
, PhD
St. Jude Children's Research Hospital
Memphis,
TN
Q&A
Jan-Henning Klusmann
, MD
University Hospital Frankfurt
Frankfurt (Main),
Germany
A Fetal Origin of Leukemia: Deciphering the Role of RUNX1 Isoforms in Trisomy 21 Associated Leukemogenesis
Jan-Henning Klusmann
, MD
University Hospital Frankfurt
Frankfurt (Main),
Germany
Q&A
December 10, 2021, 2:00 p.m. - 5:00 p.m. Eastern time
Clinical trials are a major intersection between discovery basic research and clinical applications. An expanding array of therapeutic opportunities have been made possible by advances in genomics and precision medicine, thus the clinical research enterprise needs to be capable of testing more therapies or combinations of therapies more efficiently and at a lower total cost.
To foster the clinical research enterprise, there is a need to address how clinical trials are streamlined and prioritized to improve efficiency, safety, and generalizability, while preserving scientific integrity and unbiased efficacy assessments. This is an area where basic scientists and clinicians in hematology can actively collaborate.
This workshop will foster these collaborations in a setting that addresses roadblocks to streamlining clinical trial design and execution.
Workshop Schedule
Opening Remarks
2:00 p.m. - 2:05 p.m.
Eastern time
Georgia World Congress Center, B216-B217, Level 2
Moderator:
Fangxin Hong
, PhD
Pfizer
Cambridge,
MA
The Regulatory Drug Approval Process: Getting to the Finish Line
2:06 p.m. - 3:06 p.m.
Eastern time
Georgia World Congress Center, B216-B217, Level 2
Moderators:
Willem E. Fibbe
, MD
Leiden Univ. Medical Ctr.
Leiden,
Netherlands
Jeffrey Weitz
McMaster University
Hamilton,
ON, Canada
Speakers:
Willem E. Fibbe
, MD
Leiden Univ. Medical Ctr.
Leiden,
Netherlands
Moderator Introduction
Richard F. Little
, MD,MPH
National Cancer Institute
Washington,
DC
Streamlining and Prioritizing Clinical Trials – Overview
Yoji Sato
, PhD
National Institute of Health Sciences
Kawasaki,
Japan
Regulatory Perspective - International
Angelo De Claro
, MD
US Food and Drug Administration
Bethesda,
MD
Regulatory Perspective - US
Malte Peters
, MD
Morphosys AG
Planegg,
Bavaria, Germany
Industry Perspective
Clinical Trial Challenges: From the Bench to the Patient
3:11 p.m. - 4:01 p.m.
Eastern time
Georgia World Congress Center, B216-B217, Level 2
Moderators:
Alex F. Herrera
, MD
City of Hope
Duarte,
CA
Sonali M. Smith
, MD
University of Chicago
Chicago,
IL
Speakers:
Alex F. Herrera
, MD
City of Hope
Duarte,
CA
Moderator Introduction
David P. Steensma
, MD
Novartis Institutes of Biomedical Research
Cambridge,
MA
Enhance the Interplay between Pre-Clinical and Clinical Research - from Bench to Bedside
Kannan Natarajan
, PhD
Pfizer Inc.
Peapack,
NJ
Better Data Is Key
Megan Othus
, PhD
Fred Hutchinson Cancer Research Center
Seattle,
WA
Innovative Trial Design
Lessons Learned from a Global Pandemic
4:06 p.m. - 4:56 p.m.
Eastern time
Georgia World Congress Center, B216-B217, Level 2
Moderators:
Kristen M. Sanfilippo
, MD
Washington University in St. Louis School of Medicine
Chesterfield,
MO
Neil Goldenberg
, MD,PhD
All Children's Hospital Johns Hopkins Medicine
Saint Petersburg,
FL
Speakers:
Kristen M. Sanfilippo
, MD
Washington University in St. Louis School of Medicine
Chesterfield,
MO
Moderator Introduction
Uma Borate
, MD
The Ohio State University
Columbus,
OH
Expediting Time from Concept to Enrollment
Ryan Zarychanski
, MD,MSc,FRCPC
Cancercare Manitoba University of Manitoba
Winnipeg,
MB, Canada
Novel Methods in Trial Design and Global Collaboration: Lessons from COVID-19 That Are Relevant to Patients with Hematologic Disorders
Jean M Connors
, MD
Brigham %26 Women's Hosp./Dana Farber Cancer Inst.
Boston,
MA
Prioritizing the Patients - Patients Are a Virtue
December 10, 2021, 2:00 p.m. - 5:00 p.m. Eastern time
Sickle cell disease (SCD) is the most common inherited blood disorder worldwide. Current therapeutic options are limited. However, promising drug and gene therapy related therapies renewed interest in treatment for SCD and other hemoglobinopathies. The recent cases of MDS and AML adverse events observed in patients treated with gene therapy suggest that optimization of many aspects of this therapy are needed. With the discovery of CRISPR/Cas9 system, the genome can be edited, and mutations corrected directly. However, even with this approach, current strategies require conditioning and bone marrow transplant of the corrected cells. Therefore, both gene addition and genome editing will benefit from novel techniques that may reduce the toxicity associated with conditioning and hematopoietic stem cell (HSC) manipulation.
This workshop will discuss the current challenges in gene addition and genome editing of HSC, preclinical barriers, and safety concerns. Representatives will be invited to discuss how the recent cases of MDS, and AML are shaping their policy around gene therapy and gene editing and other experts will be invited to discuss the Relevant endpoints and outcomes measures of these new therapies and initiatives to accelerate cure will be presented and discussed.
Workshop Schedule
Opening Remarks
2:00 p.m. - 2:02 p.m.
Eastern time
Georgia World Congress Center, B302-B303, Level 3
Moderators:
Stefano Rivella
, PhD
Children’s Hospital of Philadelphia
Philadelphia,
PA
Mitchell J. Weiss
, MD, Ph.D
St. Jude Children’s Research Hospital
Memphis,
TN
Manipulation of HSC and Optimization of Gene Addition Therapy
2:03 p.m. - 2:58 p.m.
Eastern time
Georgia World Congress Center, B302-B303, Level 3
Moderators:
Alexis A. Thompson
, MD, MPH
Northwestern University
Chicago,
IL
Giuliana Ferrari
, PhD
San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute
Milan,
Italy
Speakers:
Giuliana Ferrari
, PhD
San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute
Milan,
Italy
Moderator Introduction
Wendy W Pang
, MD,PhD
Jasper Therapeutics, Inc
Redwood City,
CA
Potential Alternatives to Myeloablative Chemotherapy Conditioning
Punam Malik
, MD
Cincinnati Children's Hosp.
Cincinnati,
OH
Gamma-Globin Gene Addition
Annarita Miccio
, PhD
Université de Paris, Imagine Institute, Laboratory of chromatin and gene regulation during development, INSERM UMR1163, 75015
Paris,
France
Creating HPFH Via Editing
Laura Breda
, PhD
The Children's Hospital of Philadelphia
Philadelphia,
PA
Novel Vector Modifications to Improve Synthesis of Curative Hemoglobins
Genotoxicities Associated with Genetic Therapies, Including SCD Itself
2:59 p.m. - 3:54 p.m.
Eastern time
Georgia World Congress Center, B302-B303, Level 3
Moderators:
John F. Tisdale
, MD
National Institutes of Health
Bethesda,
MD
Linzhao Cheng
, PhD
University of Science and Technology of China
Hefei,
China
Speakers:
Linzhao Cheng
, PhD
University of Science and Technology of China
Hefei,
China
Moderator Introduction
Lachelle D. Weeks
, MD,PhD
Dana Farber Cancer Institute
Boston,
MA
Development and Identification of Clonal Hematopoiesis
Courtney D. Fitzhugh
, MD
NIH (Hematology)
Bethesda,
MD
Clonal Hematopoiesis in SCD
Shengdar Q. Tsai
, PhD
St. Jude Children's Research Hospital
Memphis,
TN
Genotoxicities Associated with Genome Editing, Including SCD
Peter W. Marks
, MD, PhD
FDA
Washington,
DC
FDA Position on Addressing Genome Toxicities in SCD Related Gene Therapy Trials
Novel Approaches for Treatment of SCD
4:02 p.m. - 4:57 p.m.
Eastern time
Georgia World Congress Center, B302-B303, Level 3
Moderators:
Matthew H. Porteus
, MD, PhD
Stanford Medical School
Stanford,
CA
Kim Smith-Whitley
, MD
Children's Hospital of Philadelphia
Philadelphia,
PA
Speakers:
Kim Smith-Whitley
, MD
Children's Hospital of Philadelphia
Philadelphia,
PA
Moderator Introduction
Gerd A. Blobel
, MD, PhD
Children's Hospital of Philadelphia
Philadelphia,
PA
Targeting the HbF Pathway
Jonathan S Yen
, PhD
St. Jude Children's Research Hospital
Memphis,
TN
Base Editing for SCD
Andre Lieber
, MD, PhD
University of Washington
Seattle,
WA
In Vivo Gene Editing for SCD
Donna S. Neuberg
, ScD
Dana-Farber Cancer Institute
Boston,
MA
ASH Real World Evidence (RWE) Initiative on SCD
December 10, 2021, 2:00 p.m. - 5:00 p.m. Eastern time
This workshop will focus on technologies/diagnostics that are specific for acquired abnormalities in hematological malignancy (e.g., ctDNA and MRD testing). In addition, it will address real world application and implementation of new molecular diagnostic technologies and their translation into practice rather than the more biological/disease modelling focus of the germline predisposition workshop.
Workshop Schedule
Opening Remarks
2:00 p.m. - 2:05 p.m.
Eastern time
Georgia World Congress Center, B213-B214, Level 2
Moderators:
Piers Blombery
, MBBS
Peter MacCallum Cancer Centre
Melbourne,
Australia
Torsten Haferlach
, MD
MLL Munich Leukemia Laboratory
Munich,
Germany
Disruptive Technology in Molecular Diagnostics
2:06 p.m. - 2:45 p.m.
Eastern time
Georgia World Congress Center, B213-B214, Level 2
Moderator:
Torsten Haferlach
, MD
MLL Munich Leukemia Laboratory
Munich,
Germany
Speakers:
Torsten Haferlach
, MD
MLL Munich Leukemia Laboratory
Munich,
Germany
Moderator Introduction
Wendy N. Erber
, MD,PhD,FRCPA,FRCPath,MBA
University of Western Australia
Crawley W.A.,
WEA, Australia
Chromosomal Analysis of Immunophenotyped Cells in Suspension By Imaging Flow Cytometry (“Immuno-flowFISH”)
Aziz Nazha
Amazon Web Services
Cleveland,
OH
Artificial Intelligence in Diagnostic Hematology
Linda B Baughn
, PhD
Mayo Clinic
Rochester,
MN
Detection of Structural Variants and Copy Number Abnormalities By NGS in Hematologic Malignancies: Is It Time to Replace FISH and Chromosomes?
Circulating Tumor DNA in Diagnostics – Hope or Hype?
2:46 p.m. - 3:25 p.m.
Eastern time
Georgia World Congress Center, B213-B214, Level 2
Moderator:
David M. Kurtz
, MD,PhD
Stanford University
Stanford,
CA
Speakers:
David M. Kurtz
, MD,PhD
Stanford University
Stanford,
CA
Moderator Introduction
David M. Kurtz
, MD,PhD
Stanford University
Stanford,
CA
Novel Technologies in Circulating Tumor DNA
Imogen Caldwell
, MBBS
Peter MacCallum Cancer Centre
Melbourne,
VIC, Australia
Circulating Tumor DNA Measurements Correlate with Disease Burden and Response in Patients Undergoing CAR T-Cell Therapy
Piers Blombery
, MBBS
Peter MacCallum Cancer Centre
Melbourne,
Australia
Case Presentations - Clinical Utility of Circulating Tumor DNA in the Real World?
Novel Measurable Residual Disease (MRD) Techniques and Applications
3:35 p.m. - 4:15 p.m.
Eastern time
Georgia World Congress Center, B213-B214, Level 2
Moderator:
Ella R Thompson
, PhD, BSc
Peter MacCallum Cancer Centre
Melbourne,
Australia
Speakers:
Ella R Thompson
, PhD, BSc
Peter MacCallum Cancer Centre
Melbourne,
VIC, Australia
Moderator Introduction
Andrew H. Wei
, MBBS,PhD
The Alfred Hospital
Melbourne,
VIC, Australia
MRD Directed Therapy - a New Frontier in AML
Ing-Soo Tiong
Peter MacCallum Cancer Centre
Melbourne,
VIC, Australia
Ultra-Deep NGS for MRD Assessment in CEBPA Mutated AML
Michael Heuser
, MD
Hannover Medical School
Hannover,
Germany
Standardization of NGS-MRD
Global Efforts to Share Data and Harmonize Analytical Approaches
4:16 p.m. - 4:55 p.m.
Eastern time
Georgia World Congress Center, B213-B214, Level 2
Moderator:
Kilannin Krysiak
, PhD
Washington University In St Louis
Saint Louis,
MO
Speakers:
Kilannin Krysiak
, PhD
Washington University In St Louis
Saint Louis,
MO
Moderator Introduction
Malachi Griffith
, PhD
Washington University in St. Louis
St. Louis,
MO
A Clinical Genome Resource for Somatic Variant Interpretation in Cancer
Jennelle C. Hodge
, PhD
Indiana University
Indianapolis,
IN
The Compendium of Cancer Genome Aberrations (CCGA): Becoming a Global Hub for WHO Classification of Tumours-Based Clinical Cancer Interpretation
Daniel MacArthur
Garvan Institute of Medical Research
Darlinghurst,
NSW, Australia
Creating Global Harmonized Resources for Understanding Population Genetic Variation
December 10, 2021, 2:00 p.m. - 5:00 p.m. Eastern time
The area of immunotherapy in lymphoid malignancies has led to multiple new treatments. This proliferation of scientific knowledge has led to multiple potential new treatments including new immune checkpoint blockade therapies, novel T-cell approaches, agents targeting monocytes and macrophages, as well as new approaches inhibiting immune receptor (such as Toll-like receptors) and cytokine signaling.
This workshop seeks to address the use of immunological approaches to lymphoid malignancies while maintaining optimal immune function. The workshop will focus on the following three areas: a) lymphoid malignancies; b) immune system and tumor microenvironment; and c) current basic science to identify “what’s new” and predict “what’s next” in the world of immunotherapy.
This year’s workshop will have the theme of “Molecules versus Cells – Round 2”. It will specifically highlight the impact of immunologically active drugs, in comparison to cellular therapies, on lymphoid malignancies and discuss how these agents or cellular approaches may change clinical practice in the future. The workshop will address how novel targets, molecules, cellular therapies or biomarkers may become relevant in practice in the future.
Workshop Schedule
Moderators:
Stephen M. Ansell
, MD, PhD
Mayo Clinic
Rochester,
MN
Ronald Levy
, MD
Stanford Univ. School of Medicine
Stanford,
CA
Molecules vs Cells in the Management of Hodgkin Lymphoma
2:06 p.m. - 3:01 p.m.
Eastern time
Georgia World Congress Center, B206, Level 2
Moderators:
Stephen M. Ansell
, MD, PhD
Mayo Clinic
Rochester,
MN
Ronald Levy
, MD
Stanford Univ. School of Medicine
Stanford,
CA
Speakers:
Stephen M. Ansell
, MD, PhD
Mayo Clinic
Rochester,
MN
Moderator Introduction
Natalie S Grover
, MD
University of North Carolina at Chapel Hill
Chapel Hill,
NC
Current Results with CD30 CAR T-Cells in Hodgkin Lymphoma
Natalie S Grover
, MD
University of North Carolina at Chapel Hill
Chapel Hill,
NC
Q&A
Graham P. Collins
, MD, DPhil
Oxford University Hospitals NHS Foundation Trust
Oxford,
ENG, United Kingdom
Current Results with Camidanlumab Tesirine (Cami) in Hodgkin Lymphoma
Graham P. Collins
, MD, DPhil
Oxford University Hospitals NHS Foundation Trust
Oxford,
ENG, United Kingdom
Q&A
Molecules vs Cells in the management of B-cell lymphoma
3:05 p.m. - 4:00 p.m.
Eastern time
Georgia World Congress Center, B206, Level 2
Moderators:
Ronald Levy
, MD
Stanford Univ. School of Medicine
Stanford,
CA
Stephen M. Ansell
, MD, PhD
Mayo Clinic
Rochester,
MN
Speakers:
Ronald Levy
, MD
Stanford Univ. School of Medicine
Stanford,
CA
Moderator Introduction
Crystal L. Mackall
, MD
Stanford University School of Medicine
Stanford,
CA
Dual Targeted CAR T-Cells in B-Cell Lymphoma
Crystal L. Mackall
, MD
Stanford University School of Medicine
Stanford,
CA
Q&A
Martin Hutchings
Rigshospitalet
Copenhagen,
Denmark
Bispecific Antibodies with Increased Target Binding – Does It Matter?
Martin Hutchings
Rigshospitalet
Copenhagen,
Denmark
Q&A
Molecules vs Cells in the management of T-cell Lymphoma
4:01 p.m. - 4:56 p.m.
Eastern time
Georgia World Congress Center, B206, Level 2
Moderators:
Stephen M. Ansell
, MD, PhD
Mayo Clinic
Rochester,
MN
Ronald Levy
, MD
Stanford Univ. School of Medicine
Stanford,
CA
Speakers:
Ronald Levy
, MD
Stanford Univ. School of Medicine
Stanford,
CA
Moderator Introduction
LaQuisa C. Hill
, MD
Baylor College of Medicine, Houston Methodist Hospital
Houston,
TX
Current Results with CD5/7/30 CAR T-Cells for T-Cell Lymphoma
LaQuisa C. Hill
, MD
Baylor College of Medicine, Houston Methodist Hospital
Houston,
TX
Q&A
Paola Ghione
, MD
Roswell Park Comprehensive Cancer Center
Buffalo,
NY
Immunotherapy in T-Cell Lymphomas – Targeting T-Cells and Macrophages
Paola Ghione
, MD
Roswell Park Comprehensive Cancer Center
Buffalo,
NY
Q&A